When does the Gilenya (fingolimod) patent expire?
Gilenya (fingolimod) is covered by multiple patents and patent-style protections, and the expiration date depends on the country, the specific patent family, and whether any exclusivity extensions apply. The exact “end date” for when generic or biosimilar competitors can legally enter can also differ from the date when each individual patent expires.
Why the expiration date can vary by country (and why there isn’t one single date)
Patent expiration is not uniform across regions because:
- Different filings were made in different jurisdictions on different timelines.
- Some patents have later expiration due to continuation filings or different claim scopes.
- Regulatory data/market exclusivity (when applicable) can extend protection beyond the first patent expiry.
How to find the specific expiration date that matters for you
The most reliable way to identify the relevant expiration is to look up the specific Gilenya patent family and then match it to the country and the intended generic market. Key steps typically include:
- Identifying the jurisdiction (e.g., US vs EU vs UK vs other countries).
- Checking patent databases for “fingolimod” and the relevant assignee(s).
- Verifying which patent(s) are listed for infringement risk around generics or which patents are tied to the formulation/indications.
Are there other protections besides patents that affect generic entry?
Yes. Even after a patent expires, competitors may still face barriers from:
- Additional patents in the same family (or related families) covering different aspects (e.g., specific compositions or methods).
- Regulatory exclusivity periods (jurisdiction-dependent).
- Ongoing litigation or settlements that can delay launch.
If you tell me your country, I can narrow it to a specific date
If you share the country/region you mean (for example, the US, UK, Germany, or EU-wide), I can focus on the patents and protection windows that apply there and give a more concrete expiration timeline.